Lenvatinib administration prior to TACE could normalize abnormal tumor vessels, thereby improving intraarterial drug distribution, and could also suppress the increase in VEGF induced by hypoxia from TACE [12,13]. This evidence concerns the gene VEGFA and neoplasm.